Open AccessClinical significance of the ADVANCE study for a practitioner: Possibility to treat and prevent complications of type 2 diabetes mellitus
Author(s) -
В Н Шишкова
Publication year - 2009
Publication title -
problemy èndokrinologii
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.124
H-Index - 5
eISSN - 2308-1430
pISSN - 0375-9660
DOI - 10.14341/probl20095556-9
Subject(s) - medicine , glycemic , diabetes mellitus , blood pressure , type 2 diabetes mellitus , nephropathy , proteinuria , placebo , type 2 diabetes , randomized controlled trial , clinical trial , surgery , intensive care medicine , endocrinology , kidney , alternative medicine , pathology
ADVANCE is a multicentre placebo-controlled randomized trial undertaken to investigate effects of intensive decrease of blood pressure and blood glucose level on the development of major micro- and macrovascular complications in patients with type 2 diabetes mellitus. Patients included in the study designed to evaluate results of intense glycemic control were given glyclazide modified release (diabeton MR) as the basic treatment. The main results of ADVANCE indicate that intense hypoglycemic therapy with the use of diabeton MR allows for efficient and safe control of blood glucose level with the reduction of the mean HbA1c level to 6.5% or less. Also, this treatment significantly decreases the risk of severe diabetic complications by 10% including nephropathy and proteinuria (by 21% and 30% respectively).